803 related articles for article (PubMed ID: 28631218)
1. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
[TBL] [Abstract][Full Text] [Related]
2. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
[TBL] [Abstract][Full Text] [Related]
3. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
[TBL] [Abstract][Full Text] [Related]
4. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
[TBL] [Abstract][Full Text] [Related]
5. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
[TBL] [Abstract][Full Text] [Related]
6. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
[TBL] [Abstract][Full Text] [Related]
7. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
[TBL] [Abstract][Full Text] [Related]
8. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Fernandez HH; Boyd JT; Fung VSC; Lew MF; Rodriguez RL; Slevin JT; Standaert DG; Zadikoff C; Vanagunas AD; Chatamra K; Eaton S; Facheris MF; Hall C; Robieson WZ; Benesh J; Espay AJ
Mov Disord; 2018 Jul; 33(6):928-936. PubMed ID: 29570853
[TBL] [Abstract][Full Text] [Related]
10. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
Antonini A; Poewe W; Chaudhuri KR; Jech R; Pickut B; Pirtošek Z; Szasz J; Valldeoriola F; Winkler C; Bergmann L; Yegin A; Onuk K; Barch D; Odin P;
Parkinsonism Relat Disord; 2017 Dec; 45():13-20. PubMed ID: 29037498
[TBL] [Abstract][Full Text] [Related]
11. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
[TBL] [Abstract][Full Text] [Related]
13. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
[TBL] [Abstract][Full Text] [Related]
14. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Cannas A; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Costanzo AM; Gualberti G; Melzi G; di Luzio Paparatti U; Antonini A
Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834
[TBL] [Abstract][Full Text] [Related]
15. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
[TBL] [Abstract][Full Text] [Related]
16. Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
Kovács N; Bergmann L; Anca-Herschkovitsch M; Cubo E; Davis TL; Iansek R; Siddiqui MS; Simu M; Standaert DG; Chaudhuri KR; Bourgeois P; Gao T; Kukreja P; Pontieri FE; Aldred J
J Parkinsons Dis; 2022; 12(3):917-926. PubMed ID: 34974438
[TBL] [Abstract][Full Text] [Related]
17. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
Ray Chaudhuri K; Antonini A; Robieson WZ; Sanchez-Soliño O; Bergmann L; Poewe W;
Eur J Neurol; 2019 Apr; 26(4):581-e43. PubMed ID: 30353942
[TBL] [Abstract][Full Text] [Related]
18. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
[TBL] [Abstract][Full Text] [Related]
19. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Udd M; Lyytinen J; Eerola-Rautio J; Kenttämies A; Lindström O; Kylänpää L; Pekkonen E
Brain Behav; 2017 Jul; 7(7):e00737. PubMed ID: 28729942
[TBL] [Abstract][Full Text] [Related]
20. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
